Reuters logo
RPT-UPDATE 2-Elan, Transition drop top drug doses after deaths
December 15, 2009 / 2:47 PM / in 8 years

RPT-UPDATE 2-Elan, Transition drop top drug doses after deaths

* Nine deaths in patients on top doses of Alzheimer’s drug

* Testing of lower dose to continue in Phase II study

* Analysts say prospects for ELND005 now uncertain

* Elan shares down 2.3 percent (Adds analyst comment, shares, background on bapineuzumab)

By Ben Hirschler

LONDON, Dec 15 (Reuters) - Elan Corp ELN.I and Transition Therapeutics Inc TTH.TO have dropped the two highest doses of their experimental Alzheimer’s drug from a mid-stage clinical trial following nine deaths.

The news raised doubts as to whether the drug will now get to market, industry analysts said, although the impact on Irish-based Elan was limited as little value has so far been attributed to the product.

Elan shares were off 2.3 percent in early trade on Tuesday.

Patients will be withdrawn immediately from the Phase II study of ELND005 in the two higher dose groups, 1,000 milligrams and 2,000 mg dosed twice daily. The study will continue unchanged for patients on 250 mg, the companies said.

The decision was agreed with the Independent Safety Monitoring Committee for the 353-patient trial.

“Greater rates of serious adverse events, including nine deaths, were observed among patients receiving the two highest doses. A direct relationship between ELND005 and these deaths has not been established,” Elan and Transition said in a statement.

Elan and Transition, a small Toronto-based drugmaker, signed a worldwide development and commercialisation agreement in 2006 for the treatment.

An initial Phase I study for ELND005, an orally-administered drug, had produced encouraging results, showing that high concentrations of the drug remained in brain tissue. The data also found the treatment preserved choline acetyltransferase, an enzyme in neurons that helps protect nerve cells.

But Jack Gorman, an analyst at Davy Stockbrokers, said news of the deaths in patients on high doses considerably increased the perceived risk of the medicine reaching the market.

“At the very least efficacy at the lower dose will need to be compelling to justify development and ultimate approval,” he said. “That said, we believe that little if anything is in Elan’s share price today for its Alzheimer’s disease pipeline.”

Elan is also developing another Alzheimer’s drug called bapineuzumab with Johnson & Johnson (JNJ.N), which has a different mechanism of action and is in final-stage clinical trials.

The highest dose of bapineuzumab was also dropped from testing in April because of safety concerns.

Treating Alzheimer’s disease is a “holy grail” of drugmakers but developing effective new therapies for the degenerative brain disease has proved notoriously difficult. (Editing by David Holmes; and Hans Peters)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below